GX1 Stock Overview
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Marker Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.40 |
| 52 Week High | US$4.56 |
| 52 Week Low | US$4.36 |
| Beta | 1.54 |
| 1 Month Change | 0% |
| 3 Month Change | 0.92% |
| 1 Year Change | n/a |
| 3 Year Change | -75.28% |
| 5 Year Change | -91.45% |
| Change since IPO | -90.93% |
Recent News & Updates
Recent updates
Shareholder Returns
| GX1 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -3.1% | 1.8% |
| 1Y | n/a | -22.4% | 2.2% |
Return vs Industry: Insufficient data to determine how GX1 performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how GX1 performed against the German Market.
Price Volatility
| GX1 volatility | |
|---|---|
| GX1 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: GX1 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine GX1's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 8 | Juan Vera | markertherapeutics.com |
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells. The company also develops MT-401-OTS, which is in phase 1 clinical trial for the treatment of acute myeloid leukemia; and MT-601 which is in phase 1 clinical trial for the treatment of lymphoma, as well as in phase 1/2 clinical trial for the treatment of pancreatic cancer.
Marker Therapeutics, Inc. Fundamentals Summary
| GX1 fundamental statistics | |
|---|---|
| Market cap | €38.54m |
| Earnings (TTM) | -€12.94m |
| Revenue (TTM) | €3.05m |
12.6x
P/S Ratio-3.0x
P/E RatioIs GX1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GX1 income statement (TTM) | |
|---|---|
| Revenue | US$3.31m |
| Cost of Revenue | US$10.42m |
| Gross Profit | -US$7.11m |
| Other Expenses | US$6.94m |
| Earnings | -US$14.05m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.58 |
| Gross Margin | -214.60% |
| Net Profit Margin | -424.20% |
| Debt/Equity Ratio | 0% |
How did GX1 perform over the long term?
See historical performance and comparison